| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a94b30e055364388b4594245ed4ad5e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ecc3d6efa6a63e6af98b58efc276af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f146242850b174b114cdb31f58fb922f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f250efe89741cd3efac3d0ebd6230f00 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2012-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6bdf0092f70cc3445cf1e27460e7b68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56c3b3f428bb092ce03bd88462539ea0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_171a6a7c13cd85bbbe5d98c215e2e5c7 |
| publicationDate |
2016-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9365635-B2 |
| titleOfInvention |
Intravenous immunoglobulin composition |
| abstract |
A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titer individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titer individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titer of specific antibodies is at least 5 times higher than the average titer of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10259865-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11084870-B2 |
| priorityDate |
2005-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |